Artificial intelligence framework identifies candidate targets for drug repurposing in Alzheimer’s disease

被引：0

作者：

Jiansong Fang

Pengyue Zhang

Quan Wang

Chien-Wei Chiang

Yadi Zhou

Yuan Hou

Jielin Xu

Rui Chen

Bin Zhang

Stephen J. Lewis

James B. Leverenz

Andrew A. Pieper

Bingshan Li

Lang Li

Jeffrey Cummings

Feixiong Cheng

机构：

[1] Genomic Medicine Institute,Department of Biostatistics and Health Data Science, School of Medicine

[2] Lerner Research Institute,Department of Molecular Physiology and Biophysics

[3] Cleveland Clinic,Vanderbilt Genetics Institute

[4] Indiana University,Department of Biomedical Informatics, College of Medicine

[5] Vanderbilt University,Department of Pediatrics

[6] Vanderbilt University Medical Center,Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine

[7] Ohio State University,Harrington Discovery Institute

[8] Case Western Reserve University,Department of Psychiatry

[9] Case Western Reserve University,Institute for Transformative Molecular Medicine, School of Medicine

[10] Lou Ruvo Center for Brain Health,Department of Neuroscience

[11] Neurological Institute,Chambers

[12] Cleveland Clinic,Grundy Center for Transformative Neuroscience, Department of Brain Health, School of Integrated Health Sciences

[13] University Hospitals Cleveland Medical Center,undefined

[14] Case Western Reserve University,undefined

[15] Geriatric Psychiatry,undefined

[16] GRECC,undefined

[17] Louis Stokes Cleveland VA Medical Center,undefined

[18] Case Western Reserve University,undefined

[19] Case Western Reserve University,undefined

[20] School of Medicine,undefined

[21] University of Nevada Las Vegas,undefined

[22] Case Comprehensive Cancer Center,undefined

来源：

Alzheimer's Research & Therapy | / 14卷

关键词：

Alzheimer’s disease; Drug repurposing; Genome-wide association studies (GWAS); Multi-omics; Network medicine; Pioglitazone;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[31] Artificial intelligence technology in Alzheimer's disease research
Zhang, Wenli
Li, Yifan
Ren, Wentao
Liu, Bo
INTRACTABLE & RARE DISEASES RESEARCH, 2023, 12 (04) : 208 - 212
[32] Artificial Intelligence for Alzheimer's Disease: Promise or Challenge?
Fabrizio, Carlo
Termine, Andrea
Caltagirone, Carlo
Sancesario, Giulia
DIAGNOSTICS, 2021, 11 (08)
[33] Explainable Artificial Intelligence in Neuroimaging of Alzheimer's Disease
Khosroshahi, Mahdieh Taiyeb
Morsali, Soroush
Gharakhanlou, Sohrab
Motamedi, Alireza
Hassanbaghlou, Saeid
Vahedi, Hadi
Pedrammehr, Siamak
Kabir, Hussain Mohammed Dipu
Jafarizadeh, Ali
DIAGNOSTICS, 2025, 15 (05)
[34] A new artificial intelligence drug repurposing approach for fibromyalgia
Bonomi, Sveva
Fasano, Mauro
Alberio, Tiziana
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2023, 41 (06) : 1369 - 1369
[35] Artificial intelligence in COVID-19 drug repurposing
Zhou, Yadi
Wang, Fei
Tang, Jian
Nussinov, Ruth
Cheng, Feixiong
LANCET DIGITAL HEALTH, 2020, 2 (12): : E667 - E676
[36] Scaffold Searching of FDA and EMA-Approved Drugs Identifies Lead Candidates for Drug Repurposing in Alzheimer's Disease
Shityakov, Sergey
Skorb, Ekaterina V.
Foerster, Carola Y.
Dandekar, Thomas
FRONTIERS IN CHEMISTRY, 2021, 9
[37] Medical genetics-based drug repurposing for Alzheimer's disease
Zhang, Xiu-Zhen
Quan, Yuan
Tang, Guang-Yan
BRAIN RESEARCH BULLETIN, 2015, 110 : 26 - 29
[38] Single-cell-led drug repurposing for Alzheimer’s disease
Silvia Parolo
Federica Mariotti
Pranami Bora
Lucia Carboni
Enrico Domenici
Scientific Reports, 13 (1)
[39] Modeling Path Importance for Effective Alzheimer's Disease Drug Repurposing
Xiang, Shunian
Lawrence, Patrick J.
Peng, Bo
Chiang, Chien Wei
Kim, Dokyoon
Shen, Li
Ning, Xia
BIOCOMPUTING 2024, PSB 2024, 2024, : 306 - 321
[40] Single-cell-led drug repurposing for Alzheimer's disease
Parolo, Silvia
Mariotti, Federica
Bora, Pranami
Carboni, Lucia
Domenici, Enrico
SCIENTIFIC REPORTS, 2023, 13 (01):

← 1 2 3 4 5 →